TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03290547

Intervention type: DEVICE
Group type: OTHER
Intervention: Cutera enLighten laser
Description: Subjects will receive laser treatments.
Study: NCT00174967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
Study: NCT03858803

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Families Matter 2
Description: Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Families Matter 2
Description: Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Families Matter 2
Description: Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living as a Safer Teen
Description: Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living as a Safer Teen
Description: Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living as a Safer Teen
Description: Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
Study: NCT02704572

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection.
Study: NCT03933644

Intervention type: DEVICE
Group type: OTHER
Intervention: Gastric Tube
Description: SGA is inserted with a gastric tube as guide for insertion

Intervention type: DEVICE
Group type: OTHER
Intervention: No gastric Tube
Description: SGA is inserted without a gastric tube as guide for insertion
Study: NCT01604863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Paclitaxel + Carboplatin
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Cisplatin + Etoposide
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Docetaxel
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
Study: NCT03703011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometers positioned at the wrinkle, the hip, and the ankle
Description: Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
Study: NCT05855174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Weight protein provided in a shake with carbohydrate and water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Weight protein provided in a shake with carbohydrate and water
Study: NCT02648893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple biofortified food crops (MBFC-Exp)
Description: Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available non-fortified food crops (MBFC-C)
Description: This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
Study: NCT02996552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M & T Repair Group
Description: After the mitral valve repair a device for tricuspid annuloplasty will be implanted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral-Only Group
Description: Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
Study: NCT02716116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.
Study: NCT03256370

Intervention type: PROCEDURE
Intervention: milk collection
Description: * Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method
Study: NCT06523738

Intervention type: DIAGNOSTIC_TEST
Intervention: 1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation
Description: 1. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation

Intervention type: DIAGNOSTIC_TEST
Intervention: 1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation
Description: 1. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
Study: NCT02328092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rSMS in treatment of Nocturnal Enuresis
Description: Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rSMS in treatment of Nocturnal Enuresis
Description: Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
Study: NCT01662531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
Study: NCT02695602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdebrider-Assisted Inferior Turbinoplasty (MAIT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucous Resection with non powered instrument
Study: NCT01112514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Administered intravenously during endoscopic near-infrared (NIR) imaging
Study: NCT05859802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine Pill
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
Study: NCT02716116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.
Study: NCT03256370

Intervention type: PROCEDURE
Intervention: milk collection
Description: * Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method

Intervention type: PROCEDURE
Intervention: milk collection
Description: * Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method
Study: NCT01732926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally twice daily
Study: NCT03009877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow F&P 850™ System
Description: Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered after the ability to mask ventilate is determined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be administered after the ability to mask ventilate is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
Study: NCT05859802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
Study: NCT02461927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Naltrexone
Description: Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Placebo
Description: Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (psychoactive placebo midazolam) + Placebo
Description: Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
Study: NCT04595539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment with Attention Training Technique
Description: The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment with Attention Training Technique
Description: The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment with Attention Training Technique
Description: The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life.
Study: NCT01562912

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation Procedure
Description: Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVAC Ablation Procedure
Description: Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
Study: NCT02721641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
Study: NCT02948959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Therapies
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Controller Therapies
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study: NCT03614078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT02948959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study: NCT05258123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Description: Ginkgo biloba extract with 360mg was administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo with nine tables was administered
Study: NCT01068314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive arm exercise
Description: After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
Study: NCT01778946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Nicotine (7mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Dose Nicotine (14mg)
Study: NCT02080195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day on Days -6 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting on Day 5. Dose will be adjusted according to blood levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg three times per day from Day 5 to Day 35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: 0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 centigray on Day -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Description: Infusion on Day 0.
Study: NCT02275247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
Study: NCT04563390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality exposure therapy (P-ARET).
Description: The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure therapy
Description: The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.